Interní Med. 2006; 8(10): 454-456

NORMALIZACE SÉROLOGICKÝCH NÁLEZŮ PO ÚČINNÉ ANTIBIOTERAPII CHLAMYDIOVÝCH INFEKCÍ

doc. MUDr. Petr Hejnar Ph.D1, doc. MUDr. Milan Kolář PhD1, Mgr. Eva Hejnarová2
1 Ústav mikrobiologie FN a LF UP v Olomouci
2 SZŠ a VZŠ E. Pöttinga, Olomouc

V rámci provozu sérologické laboratoře Ústavu mikrobiologie FN a LF UP v Olomouci byli v letech 2004–2005 sledováni pacienti, u kterých došlo k vymizení chlamydiových IgA a/nebo IgM protilátek. K testování byly použity komerční soupravy „Chlamydien-IgG (IgA, IgM)-rELISA“ a „Chlamydia trachomatis-IgG (IgA)-pELISA“ (medac, Německo). Následně byla u ošetřujících lékařů ověřována klinická diagnóza, použitý antimikrobní přípravek, jeho dávkování, datum zahájení, délka terapie a její efekt.

Studovaný soubor tvořilo celkem 61 pacientů. U 57 (93,4 %) z nich šlo o vymizení rodově specifických anti-LPS IgA a/nebo IgM, u čtyř (6,6 %) o anti-Chlamydia trachomatis IgA. Nejčastějšími klinickými diagnózami byly pneumonie (13 pacientů, 21,3 %) a infekce horních cest dýchacích (8, 13,1 %). Nejfrekventněji použitými antibiotiky byly v různých dávkách azitromycin 3–11 dní (u 16 pacientů, 26,2 %), klaritromycin 7–21 dní (15, 24,6 %), doxycyklin 8–21 dní (14, 23,0 %) a jejich kombinace (zčásti s dalšími přípravky) (12, 19,7 %). K vymizení protilátek došlo za 6–235 dní od zahájení terapie – průměr 63,9 dne (medián 42).

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hejnar P, Kolář M, Hejnarová E. NORMALIZACE SÉROLOGICKÝCH NÁLEZŮ PO ÚČINNÉ ANTIBIOTERAPII CHLAMYDIOVÝCH INFEKCÍ. Interní Med. 2006;8(10):454-456.
Download citation

References

  1. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998; 91: 165-168. Go to original source... Go to PubMed...
  2. Alary M, Joly JR, Moutquin JM, Mondor M, Boucher M, Fortier A, Pinault JJ, Paris G, Carrier S, Chamberland H, Bernatchez H, Paradis JF. Randomized comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy. Lancet 1994; 344: 1461-1465. Go to original source... Go to PubMed...
  3. Alger LS, Lovchik JC. Comparative efficacy of clindamycin versus erythromycin in eradication of antenatal Chlamydia trachomatis. Am J Obstet Gynecol 1991; 165: 375-381. Go to original source... Go to PubMed...
  4. Branden E, Koyi H, Gnarpe J, Gnarpe H, Tornling G. Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection. Scand J Infect Dis 2004; 36: 811-816. Go to original source... Go to PubMed...
  5. Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis: A prospective, randomized 9-month comparison. J Rheumatol 2004; 31: 1973-1980. Go to PubMed...
  6. Critchley IA, Jones ME, Heinze PD, Hubbard D, Engler HD, Evangelista AT, Thornsberry C, Karlowsky JA, Sahm DF. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8: 214-221. Go to original source... Go to PubMed...
  7. de Barbeyrac B, Bebear C. Chlamydial pathogenesis: diagnostic and therapeutic consequences. Arch Pediatr 2005; 12 (Suppl. 1): S26-S31. Go to original source... Go to PubMed...
  8. Dylewski J, Clecner B, Dubois J, Saint Pierre C, Murray G, Bouchard C, Phillips R. Comparison of spiramycin and doxycycline for treatment of Chlamydia trachomatis genital infections. Antimicrob Agents Chemother 1993; 37: 1373-1374. Go to original source... Go to PubMed...
  9. Ferreri AJM, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell'Oro S, Doglioni C, Villa E, Boiocchi M, Dolcetti R. Regression of ocular adnexal lymphoma after Chlamydia psittaci eradicating antibiotic therapy. J Clin Oncol 2005; 23: 5067-5073. Go to original source... Go to PubMed...
  10. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-356. Go to original source... Go to PubMed...
  11. Gieffers J, Solbach W, Maass M. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther 2001; 15: 259-262. Go to original source... Go to PubMed...
  12. Haddix AC, Hillis SD, Kassler WJ. The cost-effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995; 22: 274-280. Go to original source... Go to PubMed...
  13. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, Smith P, Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178-182. Go to original source... Go to PubMed...
  14. Hejnar P, Krátká J. Prävalenz von IgA-, IgG- und IgM-Antikörpern gegen Chlamydien mit Hilfe von rekombinanten ELISA-Testen von medac bei Patienten der Universitätsklinik Olomouc und Bedeutung des IgM-Nachweises für die Diagnostik aktiver Infektionen. Mikrobiologe 2000; 10: 209-212.
  15. Henrion E, Trippaerts M, Lepage P. Severe psittacosis with multiorgan failure in a 10 year-old boy. Arch Pediatr 2002; 9: 810-813. Go to original source... Go to PubMed...
  16. Hillis SD, Coles FB, Litchfield B, Black CM, Mojica B, Schmitt K, Saint Louis ME. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women - a use-effectiveness study in public health settings. Sex Transm Dis 1998; 25: 5-11. Go to original source... Go to PubMed...
  17. Hooton TM, Batteiger BE, Judson FN, Spruance SL, Stamm WE. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36: 1144-1146. Go to original source... Go to PubMed...
  18. Jones RB, van der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39 (Suppl. B): 63-65. Go to original source... Go to PubMed...
  19. Korych B. Chlamydie a jimi vyvolané infekce. Remedia Klin Mikrobiol 1998; 2: 72-74.
  20. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma - effect of clarithromycin. Chest 2002; 121: 1782-1788. Go to original source... Go to PubMed...
  21. Kutlin A, Roblin PM, Hammerschlag MR. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 2002; 49: 763-767. Go to original source... Go to PubMed...
  22. Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 2002; 46: 409-412. Go to original source... Go to PubMed...
  23. Leinonen M. Pathogenesis of Chlamydia pneumoniae. Správy Klin Mikrobiol 2001; 1 (Suppl. C): 25-31.
  24. Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Int Med 1996; 124: 389-393. Go to original source... Go to PubMed...
  25. Mazurov VI, Lila AM. Optimization of reactive arthritis treatment using systemic enzyme therapy. Int J Immunother 2001; 17: 125-128.
  26. Medková Z. Imunologie a imunopatologie chlamydiových infekcí. Správy Klin Mikrobiol 2001; 1 (Suppl. C): 51-60.
  27. Monno R, De Vito D, Losito G, Sibilio G, Costi A, Fumarola L, D'Aprile A, Marcuccio P. Chlamydia pneumoniae in community-acquired pneumonia: Seven years of experience. J Infect 2002; 45: 135-138. Go to original source... Go to PubMed...
  28. Ossewaarde JM, Plantema FHF, Rieffe M, Nawrocki RP, Devries A, Vanloon AM. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis 1992; 11: 693-697. Go to original source... Go to PubMed...
  29. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-1303. Go to original source... Go to PubMed...
  30. Reveneau N, Crane DD, Fischer E, Caldwell HD. Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother 2005; 49: 1787-1793. Go to original source... Go to PubMed...
  31. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Int Med 1992; 116: 273-278. Go to original source... Go to PubMed...
  32. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Chlamydia LPS and MOMP seropositivity are associated with different cytokine profiles in patients with coronary heart disease. Eur J Clin Invest 2005; 35: 431-437. Go to original source... Go to PubMed...
  33. Siewert K, Rupp J, Klinger M, Solbach W, Gieffers J. Growth cycle-dependent pharmacodynamics of antichlamydial drugs. Antimicrob Agents Chemother 2005; 49: 1852-1856. Go to original source... Go to PubMed...
  34. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjala M, Sundberg S, Saikku P. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92. Go to original source... Go to PubMed...
  35. Skerk V, Schonwald S, Krhen I, Banaszak A, Begovac J, Strugar J, Strapac Z, Vrsalovic R, Vukovic J, Tomas M. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003; 21: 457-462. Go to original source... Go to PubMed...
  36. Skerk V, Schonwald S, Krhen I, Markovinovic L, Barsic B, Marekovic I, Roglic S, Zeljko Z, Vince A, Cajic V. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2002; 14: 384-389. Go to original source... Go to PubMed...
  37. Skerk V, Schonwald S, Strapac Z, Beus A, Francetic I, Krhen I, Lesko V, Vukovic J. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. J Chemother 2001; 13: 176-181. Go to original source... Go to PubMed...
  38. Stamm WE. Potential for antimicrobial resistance in Chlamydia pneumoniae. J Infect Dis 2000; 181 (Suppl. 3): S456-S459. Go to original source... Go to PubMed...
  39. Stein GE, Mummaw NL, Havlichek DH. A preliminary-study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. Pharmacotherapy 1995; 15: 727-731. Go to PubMed...
  40. Verkooyen RP, Van Lent NA, Mousavi Joulandan SA, Snijder RJ, Van den Bosch JM, Van Helden HP, Verbrugh HA. Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA. J Med Microbiol 1997; 46: 959-964. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.